New catheter aims to tame irregular heartbeat

NCT ID NCT05144503

Recruiting now Disease control Sponsor: Medtronic Cardiac Ablation Solutions Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new device called the SpherePVI catheter, which uses heat to isolate the veins that trigger atrial fibrillation. About 100 adults with symptomatic AF who haven't responded to medication will be enrolled. The main goals are to see if the procedure is safe and can successfully stop the abnormal electrical signals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SpherePVI™ Catheter with the Affera Mapping and Ablation System
What this could lead to: If successful, this could offer a safer and more effective way to control atrial fibrillation, reducing symptoms and improving quality of life.
What could go wrong: This is a small, early-stage study with no control group. The device may cause serious side effects like stroke or heart damage, and long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Vilnius University Hospital
RECRUITING

Vilnius, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.